Diabetes Clinical Trials in Honolulu

View 16 new treatments for Diabetes in Honolulu, HI near me. Every day, Power helps hundreds of Diabetes patients connect with leading medical research.
View 17 trials in Honolulu
Filter (17)

Metformin for Prediabetes

Research Clinic, Honolulu + 1 more

This trial is testing whether metformin can lower the risk of death, heart attacks, and strokes in people with pre-diabetes and heart or blood vessel issues. Metformin is a drug that helps control blood sugar levels and has been used to treat type 2 diabetes mellitus for more than 60 years. The study involves patients who have pre-diabetes and existing heart or blood vessel problems, aiming to see if metformin can provide additional health benefits.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Gregory G. Schwartz, PhD MD
Study Chair

Ranibizumab PDS Implant for Diabetic Retinopathy

Hoffmann-La Roche Clinic, 'Aiea + 1 more

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Clinical Trials
Study Director

Retatrutide vs Semaglutide for Type 2 Diabetes

Eli Lilly Clinic, Honolulu + 1 more

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Orforglipron for Obesity

Eli Lilly Clinic, Honolulu + 1 more

This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

BI 456906 for Diabetes and Obesity

Boehringer Ingelheim Clinic, Honolulu + 1 more

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Tirzepatide vs Dulaglutide for Type 2 Diabetes

Eli Lilly Clinic, Honolulu + 3 more

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

IcoSema for Type 2 Diabetes

Novo Nordisk Clinic, Honolulu + 2 more

This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. The goal is to see if it controls blood sugar better than the existing drug, semaglutide. Participants will be randomly assigned to receive either IcoSema or semaglutide for several months.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Clinical Transparency (dept. 1452)
Study Director

Retatrutide for Type 2 Diabetes and Obesity

Eli Lilly Clinic, Honolulu + 1 more

This trial is testing retatrutide, a medication for people with type 2 diabetes who are overweight or obese, including some with sleep apnea. The medication aims to help control blood sugar levels and may also aid in weight loss.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Web-Based Physical Activity for Childhood Cancer Survivor Health

Research Clinic, Honolulu + 1 more

This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Kirsten K Ness
Principal Investigator

Inclisiran for Cardiovascular Disease Prevention

Novartis Clinic, Honolulu + 1 more

This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Novartis Pharmaceuticals
Study Director
Page 1 of 2

Frequently Asked Questions

How much do diabetes clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do diabetes clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across diabetes trials in Honolulu, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for diabetes patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Honolulu is research being conducted for diabetes?

Prominent hospitals in Honolulu conducting diabetes clinical trials include the Kapiolani Medical Center for Women and Children. Several trials are also taking place in the eastern part of the city, with approximately 13 ongoing as of 2024.

What promising new drugs are being tested?

In Honolulu, diabetes research is focusing on treatments like GLP-1 Receptor Agonists and Anti-diabetic agents. Notable drugs being studied include Retatrutide, Semaglutide, and Empagliflozin.